Diagnostic, surgical and medical aspect of the midgut carcinoids

Cancer Treatment Reviews

Volumn 28, Issue 1, 2002, Pages 11-25

  De Vries, H ^a   Verschueren, R C J ^a   Willemse, P H B ^a   Kema, I P ^a   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 5 HYDROXYINDOLEACETIC ACID; AMINE; ANTINEOPLASTIC AGENT; APROTININ; BRADYKININ; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; KALLIKREIN; KALLIKREIN INHIBITOR; KETANSERIN; METHYSERGIDE; OCTREOTIDE; PENTETREOTIDE IN 111; RECOMBINANT ALPHA INTERFERON; SEROTONIN; SEROTONIN ANTAGONIST; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

ABDOMINAL ANGIOGRAPHY; ABDOMINAL RADIOGRAPHY; ANTINEOPLASTIC ACTIVITY; ARTIFICIAL EMBOLISM; BIOCHEMISTRY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CARCINOID; CARCINOID SYNDROME; CATHETER ABLATION; CHOLELITHIASIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOSURGERY; DIARRHEA; DOSE RESPONSE; ECHOGRAPHY; ELECTROCARDIOGRAPHY; FATIGUE; FLATULENCE; FLU LIKE SYNDROME; HEPATIC ARTERY LIGATION; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LIVER METASTASIS; LIVER TRANSPLANTATION; MIDGUT; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIOPERATIVE PERIOD; PROGNOSIS; REVIEW; STEATORRHEA; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR SCINTISCANNING; VOMITING; WEIGHT REDUCTION;

EID: 0036083531     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2001.0239     Document Type: Article

References (149)

1. Karzinoide Tumoren des Dunndarms
2. The classification of carcinoid tumors
3. Argentaffin and argyrophil reactions of human gastro-intestinal carcinoids
4. An analysis of 8305 cases of carcinoid tumors
5. Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth
6. The incidence, management, and outcome of patients with gastrointestinal carcinoids and second primary malignancies
7. Carcinoid tumors in Denmark 1978-1989 and the risk of subsequent cancers. A population-based study
8. Carcinoid tumours. Frequency in a defined population during a 12-year period
9. Prognostic variables in patients with gastrointestinal carcinoid tumours
10. Carcinoid tumours of the gastrointestinal tract
11. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival
12. Carcinoid tumours in the gastrointestinal tract - An analysis of 156 cases
13. The role of the physician in the late diagnosis of primary malignant tumors of the small intestine
14. Intussusception in adults
15. Karnofsky memorial lecture. An Odyssey in the land of small tumors
16. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors
17. Carcinoid tumors. A study of 204 cases
18. Carcinoids of the jejunum and ileum: An immunohistochemical and clinicopathologic study of 167 cases
19. Surgical treatment of mid-gut carcinoid tumors
20. The malignant carcinoid syndrome
21. Treatment of the carcinoid tumor and the malignant carcinoid syndrome
22. Surgical therapy for small-bowel carcinoid tumors
23. Carcinoid tumors, vascular elastosis, and ischemic disease of the small intestine
24. Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids
25. Sublingual nitrate provides cause for fear of food in a carcinoid patient
26. Elastic vascular sclerosis of mesenteric blood vessels in argentaffin carcinoma
27. High expression of growth factors and growth factor receptors in ovarian metastases from ileal carcinoids: An immunohistochemical study of 2 cases
28. Dopamine, norepinephrine and serotonin production by an intestinal carcinoid tumor
29. Increased dopamine production in patients with carcinoid tumors
30. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors
31. Progressive carcinoid heart disease after resection of primary ovarian carcinoid
32. Carcinoid syndrome due to a primary ovarian carcinoid tumour
33. Substance P in the localization of a carcinoid tumor
34. Histamine in carcinoid syndrome
35. Serotonin, catecholamines, and spontaneous midgut carcinoid flush: Plasma studies from flushing and nonflushing sites
36. Bradykinin in carcinoid syndrome
37. Evidence for a 5-HT4 receptor pathway mediating chloride secretion in the rat distal colon
38. The 5-HT4 receptor mediates 5-hydroxytryptamine-induced rise in short circuit current in the human jejunum in vitro
39. A 5-HT2 receptor mediates serotonin-induced electrolyte transport in rat left colon
40. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome
41. Motilin in plasma and tumor tissues from patients with the carcinoid syndrome. Possible involvement in the increased frequency of bowel movements
42. Tachykinins in carcinoid tumors: Their use as a tumor marker and possible role in the carcinoid flush
43. Urinary serotonin in the diagnosis of carcinoid tumors
44. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echo-cardiography
45. Incidence and evolution of carcinoid syndrome in the heart
46. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin
47. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center
48. Neuroendocrine gastrointestinal tumours
49. Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours
50. Carcinoid tumors of the alimentary tract. I. Radiographic diagnosis
51. The roentgenologic spectrum of small intestinal carcinoid tumors
52. Angiography, computed tomography, magnetic resonance imaging and ultrasonography in detection of liver metastases from endocrine gastrointestinal tumours
53. Carcinoid tumors of the gastrointestinal tract: Evaluation with endoscopic ultrasonography
54. Midgut carcinoid tumours. CT appearance
55. Computed tomography of abdominal carcinoid tumors
56. Computed tomography of abdominal carcinoid tumor
57. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): A comparative study with CT and MR imaging
58. Limitations of angiography for mesenteric ischemia caused by midgut carcinoid tumors
59. Somatostatin receptors in human endocrine tumors
60. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas
61. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin
62. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs
63. Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radiolig and uptake and tumor markers
64. Somatostatin receptor imaging: Predicative and prognostic considerations
65. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors
66. Human biodistribution on [111In]diethylenetriaminepentaacetic acid-(DTPA)-D-[Phe1]-octreotide and perioperative detection of endocrine tumors
67. Value of somatostatin receptor scintigraphy for pre-operative localization of carcinoids
68. Scintigraphic imaging of carcinoid tumours with 131I-metaiodobenzylguanidine
69. Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors
70. Comparison of somatostatin aalogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours
71. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours
72. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue
73. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide
74. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes
75. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms
76. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors
77. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors
78. Gastroenteropancreatic endocrine tumours: Effect of Sandostatin on tumour growth
79. The role of interferons in the management of carcinoid tumors
80. The role of interferons in the management of carcinoid tumours
81. Recombinant interferon alpha-2b in patients with metastatic apudomas: Effect on tumours and tumour markers
82. Interferons in the management of neuroendocrine tumors and their possible mechanism of action
83. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome
84. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors
85. Treatment of malignant carcinoid tumors: A randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon
86. Localization procedures in pheochromocytoma and neuroblastoma
87. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors
88. Comparison of Somatostatin Analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors
89. Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine
90. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors
91. Management of disseminated midgut carcinoid tumours
92. The role of surgery in patients with advanced midgut carcinoid tumours
93. Abdominal surgery in patients with midgut carcinoid tumors
94. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum
95. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction
96. Method for dissection of mesenteric metastases in midgut carcinoid tumors
97. Follow-up of 102 patients operated on for gastrointestinal carcinoid
98. Carcinoid tumors
99. Ileal carcinoid tumors and intestinal ischemia
100. A study of the histopathogenesis of carcinoid tumors of the small intestine and appendix
101. Carcinoid tumor of the appendix: Treatment and prognosis
102. Carcinoid tumours of the appendix
103. Incidence and mortality of carcinoids of the colon
104. Cytoreductive hepatic surgery for neuroendocrine tumors
105. The pentagastrin test as an indicator of a cure in surgically treated patients with advanced carcinoid disease
106. Liver blood flow in man during abdominal surgery. II. The effect of hepatic artery occlusion on the blood flow through metastatic tumor nodules
107. Effects of experimental hepatic artery embolization on hepatic function
108. Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs
109. Carcinoid liver metastases treated with hepatic dearterialization
110. Treatment of carcinoid liver metastases by hepatic-artery embolisation
111. Embolisation therapy in the midgut carcinoid syndrome: Just tumour ischaemia?
112. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors
113. The management of patients with advanced carcinoid tumors and islet cell carcinomas
114. Gangrenous cholecystitis as a complication of hepatic artery embolization: Case report
115. Hepatic abscess formation following embolization of a carcinoid metastasis
116. Side effects and complications after hepatic artery embolization in the carcinoid syndrome
117. Cryoablation of unresectable malignant liver tumors
118. Cryosurgical debulking of unresectable liver metastases for palliation of carcinoid syndrome
119. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors
120. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy
121. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases
122. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases
123. Liver transplantation for metastatic carcinoid tumors
124. Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver
125. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report
126. Outcome of cardiac surgery for carcinoid heart disease
127. Predictors of outcome of tricuspid value replacement in carcinoid heart disease
128. Metastatic carcinoid syndrome treated with methysergide
129. Carcinoid tumors: Pharmacological therapy
130. Ketanserin, a 5-HT antagonist, in symptomatic treatment of carcinoid syndrome
131. Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial
132. Somatostatin, gastro-intestinal peptides, and the carcinoid syndrome
133. Efficacy of somatostatin in a patient with carcinoid syndrome
134. Rapid reversal of carcinoid crisis with a somatostatin analogue
135. Octreotide treatment of carcinoid hypertensive crisis
136. Carcinoid crisis after biopsy of a bronchial carcinoid
137. Theoretical and clinical considerations in anaesthesia for secreting carcinoid tumors
138. Neuropeptide K: A major tachykinin in plasma and tumor tissues from carcinoid patients
139. Carcinoid heart disease: Relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities
140. Anaesthesia for the carcinoid syndrome: A report of nine cases
141. Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome
142. Anesthesia for patients with carcinoid syndrome
143. Use of arterial devascularization and cytotoxic drugs in 30 patients with the carcinoid syndrome
144. Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine
145. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin-alone or in combination with 5-FU
146. Carboplatin in the treatment of metastatic carcinoid tumours and paraganglioma: A phase II study
147. A pilot study of combination therapy with interferon alpha-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours
148. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms